Rapid analysis of MM1270B, an inhibitor of matrix metalloproteases in human plasma by liquid chromatography-tandem mass spectrometry: Matrix interference in patient samples

Biomedical Chromatography

Volumn 18, Issue 2, 2004, Pages 77-85

  Majumdar, Tapan K ^a,b   Vedananda, Sunanda ^a   Tse, Francis L S ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chromatography; Matrix validation; Metalloprotease; Spectrometry

Indexed keywords

ATMOSPHERIC IONIZATION; ATMOSPHERIC PRESSURE; CHROMATOGRAPHIC ANALYSIS; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; PLASMA (HUMAN);

ANALYTES; CHROMATOGRAPHIC SEPARATIONS; HUMAN PLASMAS; MATRIX; MATRIX METALLOPROTEASE; MATRIX VALIDATION; METALLO-PROTEASE; MONITORING MODE; SELECTED REACTION MONITORING; SIMPLE++;

MASS SPECTROMETRY;

CGS 26835A; CGS 27023A; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MMI 270B; UNCLASSIFIED DRUG; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SULFONAMIDE;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; ATMOSPHERIC DISPERSION; BLOOD SAMPLING; CASE REPORT; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; DRUG STRUCTURE; FILTRATION; HUMAN; IONIZATION; LINEAR SYSTEM; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; SIGNAL NOISE RATIO; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; BLOOD; DRUG ANTAGONISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

CHROMATOGRAPHY, LIQUID; HUMANS; HYDROXAMIC ACIDS; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; PYRAZINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 1842503148     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.295     Document Type: Article

References (17)

1. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. Journal of the National Cancer Institute 1991; 83: 775.
2. Buhrman DL, Price PI, Rudewicz PJ. Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: A study of ion suppression. Journal of the American Society of Mass Spectrometry 1996; 7: 1099.
3. Bonfiglio R, King RC, Olah TV, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175.
4. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Research 1993; 53: 5365.
5. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: Present achievements and future prospects. Investigation of New Drugs 1997; 15: 175.
6. Docherty AJ, O'Connell J, Crabbe T, Angal S, Murphy G. The matrix metalloproteinase and their natural inhibitors: Prospects for treating degenerative tissue diseases. Trends in Biotechnology 1992; 10: 200.
7. Doughty JR, O'Byrne E, Spirito S, Blancuzzi V, Singh HN and Goldberg RL. The effect of CGS 27023A on the level of 3B3 (-)epitope in a rebbit meniscectomy model. Inflammation Research 1997; 46(Suppl. 2): S139.
8. Eskens FALM, Levitt NC, Sparreboom A, Choi L, Mather R, Verweij J and Harris AL. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. Clinical Cancer Research 2000; 6: 431.
9. Jamel M, Xia YQ. The need for adequate chromatographic separation in the quantitative determination of drugs in biological samples by high performance liquid chromatography with tandem mass spectrometry. Rapid Communications in Mass Spectrometry 1999; 13: 97.
10. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. Journal of the National Cancer Institute 1994; 86: 299.
11. Kishi J, Tanaka R, Koiwai O, Yamagata S, Numata Y, Hayakawa T, Shimizu S. Gelatinases and metalloproteinase inhibitor secreted by murine colonic carcinoma cells with differing metastatic potential. Cell Biology International 1994; 18: 165.
12. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991; 64: 327.
13. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Research 1993; 53: 4493.
14. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V and Parker DT. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. Journal of the Medical Chemistry 1997; 40: 2525.
15. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: A method for determination of finasteride in human plasma at picogram per milliliter concentrations. Analytical Chemistry 1998; 70: 882.
16. Matuszewski BK, Chavez-Eng CM, Constanzer ML. Development of high-performance liquid chromatography-tandem mass spectrometric methods for the determination of a new oxytocin receptor antagonist (L-368,899) extracted from human plasma and urine: A case for lack of specificity due to the presence of betabolites. Journal of Chromatography B 1998b; 716: 195.
17. Rowland M, Tozar TN. Clinical Pharmacokinetics: Concepts and Applications, 2nd edn. Lea & Febiger: Philadelphia, PA. 1989; 459.